Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Arcus Biosciences (RCUS)

Arcus Biosciences Q2 revenue rises to $39 million; net loss widens to $93 million

Mixed Impact 3 of 5 earnings Written later

Arcus Biosciences reported second-quarter 2024 revenue of $39 million, up from $29 million a year earlier, while its net loss widened to $93 million from $75 million as research and development expenses rose to $115 million from $84 million. Cash, cash equivalents and marketable securities totaled $1.0 billion at June 30, 2024, and the company said that balance will fund operations into 2027.

Key points

  • Q2 2024 revenue was $39 million versus $29 million in Q2 2023; six-month revenue was $184 million versus $54 million.
  • Q2 net loss was $93 million versus $75 million; net loss per share was $1.02 versus $1.04.
  • R&D expenses were $115 million versus $84 million, driven by higher clinical trial and headcount-related costs for late-stage programs.
  • Cash and marketable securities were $1.0 billion at June 30, 2024, including $320 million received from Gilead for its January 2024 equity investment.

The filing

CompanyArcus Biosciences (RCUS)
Form8-K, current report
Filed with the SECAug 8, 2024, 4:09 PM ET
Accession number0001724521-24-000136

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:49 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 08, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.